TL;DR: Adding thyroid RFA can improve ROI across interventional radiology, endocrine surgery, head and neck surgery, and endocrinology by creating an outpatient, thyroid-preserving pathway for selected benign nodules. The value may appear through patient retention, added procedural capacity, referral continuity, or protected OR time.
- Thyroid RFA gives four thyroid care specialties a minimally invasive option for selected benign nodules that may not warrant thyroidectomy.
- Clinical value is supported by nodule volume reduction, symptom improvement, scar avoidance, outpatient treatment, and thyroid hormone preservation.
- Outpatient workflows can create procedural capacity and may free OR access for thyroid cancer or complex endocrine surgeries.
- Dedicated 2025 CPT codes improve claim specificity, while device selection and training support repeatable program adoption.
Thyroid RFA can create clinical and operational value across interventional radiology, endocrine surgery, head and neck surgery, and endocrinology. ROI may appear through treatment capacity, patient retention, referral continuity, reimbursement readiness, or protected OR time.
The procedure gives clinicians a minimally invasive option for selected benign nodules when observation is unsatisfying but thyroidectomy feels disproportionate. For practices developing a broader thyroid care pathway, RFA can complement surveillance and surgery rather than replace either one.
Continue reading to learn where the clinical and financial value comes from, and what practices should consider before launching a thyroid RFA program.
Why Add Thyroid RFA to a Thyroid Care Practice?
Thyroid RFA is an ultrasound-guided, thyroid-preserving procedure that thermally ablates targeted nodule tissue. For patients considering endocrine surgeries for benign nodules, RFA for thyroid can reduce nodule volume without a neck incision or the need for general anesthesia. Many RFA patients are able to avoid routine lifelong thyroid hormone replacement by opting out of thyroid removal.
According to the American Thyroid Association, RFA benefits may include:
- Nodule volume reduction
- Symptom and cosmetic improvement
- Scar avoidance
- Thyroid hormone preservation
- Outpatient treatment
- Faster recovery than surgery
How Thyroid RFA Creates Value Across Four Specialties
The clinical and operational value of thyroid RFA varies by specialty, but each can use it to expand care for appropriately selected benign nodules. The procedure can strengthen existing workflows, support coordinated referrals, and give more patients access to thyroid-preserving treatment.
- Interventional Radiology: Adds an outpatient procedure that fits existing ultrasound-guided treatment expertise.
- Endocrine Surgery: Gives an endocrine surgery clinic a nonsurgical pathway for eligible benign nodules and may preserve OR capacity.
- Head and Neck Surgery: Expands thyroid-preserving care while retaining surgery for malignant or anatomically unsuitable nodules.
- Endocrinology: Extends care beyond surveillance through in-practice treatment or coordinated referral.
Together, these pathways can keep more appropriate patients within the same network and preserve surgery for malignant or anatomically unsuitable cases.
Where Does the ROI Come From?
Clinical ROI starts with positive outcomes. In the 2025 RATED study, investigators reported a median thyroid nodule volume reduction of 70.8% at 12 months after the initial learning curve, with no major complications in the cohort. The same study found treatment efficacy stabilized after roughly 20 cases per center, underscoring the role of structured training and repeatable technique.
Thyroid RFA is typically performed under local anesthesia in an outpatient setting. That can add procedural capacity for interventional radiology or endocrinology and protect OR time for complex endocrine surgeries. At a hospital for endocrine surgery or multidisciplinary thyroid center, it may also strengthen referrals without leaving benign nodule patients underserved.
Reimbursement and Practice Planning
ROI also depends on clean operational planning. Dedicated U.S. CPT codes 60660 and 60661 became effective for thyroid RFA in 2025, replacing prior unlisted-code reporting and improving claim specificity.
CMS also maintains the Physician Fee Schedule Look-Up Tool for Medicare payment information, RVUs, and payment policies, giving practices a more transparent starting point for payer discussions.
Your thyroid RFA launch plan should include eligibility checks, cytology documentation, ultrasound mapping, informed consent language, post-procedure follow-up, and payer-specific prior authorization workflows. Endocrine surgery clinics should also clearly define which cases should always be treated with surgery, including suspicious cytology, significant substernal extension, or anatomy that cannot be safely visualized.
Device and Training Considerations
Device selection should support controlled energy delivery, ultrasound-guided maneuverability, active tip options, and physician confidence in delicate cervical anatomy. Training matters just as much as equipment, since early cases shape efficiency and outcomes.
The STARMED RF System or STARMED’s VIVA combo RF System is currently the only RF system in the United States with an FDA-cleared indication specifically for thyroid nodule ablation. The clearance applies to the VIVA combo RF generator with Star RF Electrodes and VIVA RF Electrodes for ultrasound-guided percutaneous ablation of eligible benign thyroid nodules.
Learn More About Thyroid RFA
STARMED America offers thyroid-focused RFA technology and physician education resources designed to support safe adoption across interventional radiology, endocrine surgery, head and neck surgery, and endocrinology. Explore how Thyroid RFA can support a thyroid-preserving care pathway in your practice.
